Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Patients with rare solid tumors treated on early phase trials experience toxicities from their tumors and treatments. However, limited data exist to describe the detailed symptom burden suffered by these patients, particularly those with rare solid tumors treated with immunotherapy. We performed a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendoza, Tito R., Hong, David S., Peterson, Christine B., Stephen, Bettzy, Dumbrava, Ecaterina, Pant, Shubbam, Tsimberidou, Apostolia Maria, Yap, Timothy Anthony, Sheshadri, Ajay, Altan, Mehmet, George, Goldy, Castillo, Lilibeth, Rodriguez, Enedelia, Gong, Jing, Subbiah, Vivek, Janku, Filip, Fu, Siqing, Piha-Paul, Sarina A., Ahnert, Jordi Rodon, Karp, Daniel D., Cleeland, Charles, Meric-Bernstam, Funda, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399082/
https://www.ncbi.nlm.nih.gov/pubmed/35999229
http://dx.doi.org/10.1038/s41598-022-16588-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399082/
https://www.ncbi.nlm.nih.gov/pubmed/35999229
http://dx.doi.org/10.1038/s41598-022-16588-3

Ejemplares similares